Mont-Saint-Guibert, Belgium, 13 December 2024, 17:30 CET – BIOSENIC (Euronext Brussels and Paris : BIOS) announces the signing of a conditional letter of intent between Medsenic SAS and the Singapore based TrialCap Pte. Ltd. as a first step for a proposed financing arrangement through both debt and equity subscription. Final agreements are yet to be concluded between the two companies – which cannot be guaranteed at this stage – and, if finalized, the financing will among others remain contingent on the creation of an Australian subsidiary by Medsenic and the acquisition of additional resources necessary for carrying out the clinical trial. Medsenic is hence actively seeking the additional funding required to execute its program and initiate research, which is supported by the positive Phase 2 results and promising preclinical trials of its experimental drug in an oral formulation of its active ingredient, arsenic trioxide (ATO).
